A quiet analytical research laboratory at night, racks of glass vials along a dim bench.

NMN+ Nano (In Development)

NMN+ Nano is nano-encapsulated nicotinamide mononucleotide, formulated for stability and bioavailability as a NAD+ precursor. It is in development and not on sale; availability depends on the regulatory pathway in each market.

Why NMN needs a delivery system

NMN is a water-soluble nucleotide of 334 Da that is hygroscopic and hydrolyzes to nicotinamide under heat and humidity, so powder quality drifts in ordinary capsules. After ingestion, much of it is converted in the gut and liver, and human studies show that oral NMN raises downstream NAD+ metabolites in blood rather than intact NMN. Whether a dedicated intestinal transporter (Slc12a8, reported in mice) matters in humans is still debated.

Evidence tier

Animal evidence is substantial: long-term NMN in mice mitigated several age-associated physiological declines. Human evidence is limited to small trials. A 10-week study in postmenopausal women with prediabetes found increased muscle insulin sensitivity, while other trials show good tolerability and higher blood NAD+ metabolites with mixed functional outcomes. We treat NMN as a well-characterized precursor with early human data, not an established intervention. Most published human trials are short, involve fewer than 100 participants and use plain NMN powder rather than any encapsulated form.

Regulatory status

In the United States, FDA confirmed in September 2025 that NMN is not excluded from the dietary supplement definition, reversing its 2022 position; new dietary ingredient requirements still apply. Status differs elsewhere, including Canada and the EU, where novel food rules may apply. NMN is not on the WADA Prohibited List. Statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure or prevent any disease.

Key facts

Twelve months of NMN supplementation mitigated age-associated physiological decline in mice (Mills et al. 2016, Cell Metab)
NMN increased muscle insulin sensitivity in a 10-week trial in 25 prediabetic postmenopausal women (Yoshino et al. 2021, Science)
Slc12a8 was identified as an NMN transporter in the mouse small intestine (Grozio et al. 2019, Nat Metab)
FDA stated in September 2025 that NMN is lawful in dietary supplements (FDA response to Natural Products Association, 2025)

How our delivery technology applies

The first job is shelf stability: an inner hydrophobic layer and moisture barrier slow hydrolysis to nicotinamide, which is the main quality failure in NMN powders. Outer pH-responsive layers can shift release toward the small intestine rather than the stomach. We are measuring whether that changes the pattern of NAD+ metabolites in blood compared with plain NMN; until data exist, we claim improved stability as the design goal, not higher bioavailability.

Discuss licensing NMN+ Nano for your market.